Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Pathology|April 29, 2016
Evaluation of Fluorescently Labeled Aerolysin as a New Kind of Reagent for Flow Cytometry Tests: Optimization of Use of FLAER, Hints, and LimitsAbdelmalek Dahmani, Hervé Roudot, Florence Cymbalista, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 10, 2009
Flow cytometry APC-tandem dyes are degraded through a cell-dependent mechanismChristine Le Roy, Nadine Varin-Blank, Florence Ajchenbaum-Cymbalista, et al.
Journal of Clinical Pathology|August 4, 2016
HBME-1 is expressed by erythroid precursors in early maturation stage and can be a valuable tool for evaluation of dyserythropoiesis in bone marrow core biopsy specimensRiad Arana, Daniel Lusina, Thorsten Braun, et al.
Annales De Biologie Clinique|May 16, 2026
[Flow cytometry image atlas: lymphoproliferative syndromes - Additional images obtained on the XF1600]Julie Sevestre, Caroline Mayeur-Rousse, Sabrina Imbert, et al.
British Journal of Haematology|February 14, 2002
Absence of mutations in the HoxA10, HoxA11 and HoxD11 nucleotide coding sequences in thrombocytopenia with absent radius syndromeRoger A Fleischman, Rémi Letestu, Xiafang Mi, et al.
Leukemia & Lymphoma|August 23, 2011
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Eric Van Den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, et al.
American Journal of Clinical Pathology|November 18, 2015
Evaluation of paroxysmal nocturnal hemoglobinuria screening by flow cytometry through multicentric interlaboratory comparison in four countriesAgathe Debliquis, Orianne Wagner-Ballon, Magali Le Garff-Tavernier, et al.
Annales De Biologie Clinique|September 13, 2019
[A primitive plasma cell leukemia with immunoglobulin (Ig) E]Meriem Rachidi, Gregory Lazarian, Rémi Letestu, et al.
Annales De Biologie Clinique|October 21, 2023
Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patientsVictor-Emmanuel Brett, Marie-Sarah Dilhuydy, Nicolas Lechevalier, et al.
Leukemia & Lymphoma|November 22, 2021
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO studyAnne Laure Gagez, Franciane Paul, Elina Alaterre, et al.
Pageof 4